右美托咪定与丙泊酚预防成人氯胺酮程序化镇静后恢复期躁动的比较研究:一项随机双盲临床试验
该前瞻性随机双盲临床试验纳入93例在急诊接受有痛操作成人,随机分为三组:氯胺酮复合右美托咪定组(右美托咪定0.7 μg/kg+氯胺酮1 mg/kg)、氯胺酮复合丙泊酚组(丙泊酚0.5 mg/kg+氯胺酮0.5 mg/kg)和单用氯胺酮组(氯胺酮1 mg/kg),均静脉给药。结果显示恢复期躁动发生率在复合右美托咪定组为26%、复合丙泊酚组为29%、单用氯胺酮组为58%;复合右美托咪定组与单用氯胺酮组发生率差为32%(95%CI 9-56),复合丙泊酚组与单用氯胺酮组差为29%(95%CI 6-53)。严重躁动在单用氯胺酮组显著更高。结论提示两种复合方案均能降低成人急诊程序化镇静中氯胺酮所致恢复期躁动的发生率和严重程度。
要点
- 在急诊成人程序化镇静中,氯胺酮复合右美托咪定(0.7 μg/kg+1 mg/kg)较单用氯胺酮(1 mg/kg)降低恢复期躁动发生率32%(95%CI 9-56)。
- 氯胺酮复合丙泊酚(0.5 mg/kg+0.5 mg/kg)较单用氯胺酮降低恢复期躁动发生率29%(95%CI 6-53)。
- 单用氯胺酮组严重躁动显著高于复合右美托咪定组(差19%,95%CI 6-33)和复合丙泊酚组(差16%,95%CI 1-31)。
- 三组在人口学特征、操作类型、疼痛评分、镇静前躁动和操作时长方面无显著差异。
适用人群与场景
- 年龄18岁及以上、在急诊科拟接受有痛操作的成人患者。
诊断标准与关键阈值
- 采用Richmond Agitation-Sedation Scale(RASS)评估恢复期躁动的发生率和严重程度。
处置流程与药物剂量
- 第一组:静脉给予右美托咪定0.7 μg/kg与氯胺酮1 mg/kg(ketadex组)。
- 第二组:静脉给予丙泊酚0.5 mg/kg与氯胺酮0.5 mg/kg(ketofol组)。
- 第三组:静脉给予氯胺酮1 mg/kg单药(ketamine组)。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:前瞻性、随机、双盲临床试验;样本量93例,单中心急诊科;人群为18岁以上接受有痛操作的成人。
- 干预与对照:三组分别接受ketadex(右美托咪定0.7 μg/kg+氯胺酮1 mg/kg)、ketofol(丙泊酚0.5 mg/kg+氯胺酮0.5 mg/kg)或单用氯胺酮1 mg/kg,均静脉给药。
- 主要终点:恢复期躁动发生率ketadex组26%、ketofol组29%、ketamine组58%;ketadex vs ketamine差32%(95%CI 9-56),ketofol vs ketamine差29%(95%CI 6-53)。
- 关键次要终点:严重躁动在ketamine组显著更高,ketamine vs ketadex差19%(95%CI 6-33),ketamine vs ketofol差16%(95%CI 1-31)。
- 三组人口学特征、操作类型、疼痛评分、镇静前躁动和操作时长无显著差异。
证据类型、等级与局限
- 证据类型:随机双盲临床试验;证据等级或推荐强度原文未提及;局限包括单中心、样本量较小(93例)。
对床旁实践的改变
- 在急诊成人程序化镇静中,使用氯胺酮复合右美托咪定或复合丙泊酚可降低氯胺酮所致恢复期躁动的发生率和严重程度,可考虑替代单用氯胺酮。
- 适用人群为18岁及以上在急诊接受有痛操作的成人;不适用人群原文未提及。
- 常见陷阱原文未提及。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The present study was designed to evaluate the effect of dexmedetomidine and propofol on ketamine-induced recovery agitation in adults when used as co-administration with ketamine.
METHODS: In this prospective, randomized, and double-blind clinical trial, 93 patients aged 18 years or older who were candidates for painful procedures in the emergency department (ED) were enrolled and assigned into three equal groups to receive either ketadex (dexmedetomidine 0.7 μg/kg and ketamine 1 mg/kg), ketofol (propofol 0.5 mg/kg and ketamine 0.5 mg/kg) or ketamine alone (1 mg/kg) intravenously. Incidence and severity of recovery agitation were evaluated using the Richmond Agitation-Sedation Scale and compared between groups.
RESULTS: There were no significant differences in demographic characteristics, procedures, pain scores, pre-sedation agitation, and duration of procedure between the three groups. The incidence of recovery agitation was 26% in the Ketadex group, 29% in the Ketofol group, and 58% in the Ketamine group. The difference in incidence of recovery agitation between Ketadex group and Ketamine group was 32% (95% confidence interval (CI), 9 to 56]) and between Ketofol group and Ketamine group was 29% (95% CI, 6 to 53). The severe agitation was significantly higher in Ketamine group, with a difference between Ketamine and Ketadex group of 19% (95% CI, 6 to 33), and a difference between Ketamine and Ketofol group of 16% (95% CI, 1 to 31).
CONCLUSIONS: In this study, a combination of ketamine-dexmedetomidine and ketamine-propofol reduced the incidence and severity of ketamine-induced recovery agitation in adults undergoing procedural sedation in the ED.
参考来源
- Azizkhani R, Kouhestani S, Heydari F, et al. A comparative study of dexmedetomidine and propofol to prevent recovery agitation in adults undergoing procedural sedation with ketamine: A randomized double-blind clinical trial. Am J Emerg Med. 2021. PMID: 34371324. doi:10.1016/j.ajem.2021.07.059
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。